4579.T JPX
RaQualia Pharma Inc.
1W: +0.3%
1M: +7.6%
3M: +28.8%
YTD: -40.7%
1Y: -2.7%
3Y: -15.5%
5Y: -46.4%
¥607.00 ($3.85)
-2.00 (-0.33%)
Weekly Expected Move ±4.9%
¥550
¥579
¥609
¥639
¥668
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$4.0B
+28.1% ▲
5Y CAGR: +29.2%
Gross Profit
$3.3B
+31.7% ▲
5Y CAGR: +27.5%
Operating Income
$484M
+326.7% ▲
Net Income
$273M
+155.2% ▲
EPS (Diluted)
$11.36
+149.7% ▲
EBITDA
$972M
+416.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.8B | $2.9B | $1.9B | $3.1B | $4.0B |
| YoY Growth | +150.7% | +5.1% | -34.8% | +63.5% | +28.1% |
| Cost of Revenue | $321M | $232M | $245M | $626M | $712M |
| Gross Profit | $2.5B | $2.7B | $1.7B | $2.5B | $3.3B |
| Gross Margin | 88.4% | 92.1% | 87.1% | 79.9% | 82.1% |
| R&D Expenses | $1.1B | $1.2B | $1.4B | $1.7B | $1.6B |
| SG&A Expenses | $620M | $572M | $621M | $991M | $1.2B |
| Operating Expenses | $1.7B | $1.8B | $2.0B | $2.7B | $2.8B |
| Operating Income | $708M | $866M | -$337M | -$213M | $484M |
| Operating Margin | 25.5% | 29.7% | -17.7% | -6.9% | 12.2% |
| Interest Expense | $1M | $6M | $7M | $184M | $59M |
| Income Before Tax | $881M | $851M | -$294M | -$358M | $438M |
| Tax Expense | $125M | $128M | $30M | $137M | $165M |
| Net Income | $756M | $723M | -$324M | -$495M | $273M |
| Net Margin | 27.2% | 24.8% | -17.0% | -15.9% | 6.9% |
| EPS (Diluted) | $36.04 | $34.47 | $-14.98 | $-22.87 | $11.36 |
| EBITDA | $1.0B | $1.0B | -$112M | $188M | $972M |
| Shares Outstanding | 21M | 21M | 22M | 22M | 24M |